Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

AMPK is an energy sensor modulating metabolism, inflammation, and a target for metabolic disorders. Metabolic dysfunction results in lower AMPK activity. PXL770 is a direct AMPK activator, inhibiting de novo lipogenesis (DNL) and producing efficacy in preclinical models. We aimed to assess pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouqueray, Pascale, Bolze, Sebastien, Dubourg, Julie, Hallakou-Bozec, Sophie, Theurey, Pierre, Grouin, Jean-Marie, Chevalier, Clémence, Gluais-Dagorn, Pascale, Moller, David E., Cusi, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714938/
https://www.ncbi.nlm.nih.gov/pubmed/35028615
http://dx.doi.org/10.1016/j.xcrm.2021.100474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714938/
https://www.ncbi.nlm.nih.gov/pubmed/35028615
http://dx.doi.org/10.1016/j.xcrm.2021.100474

Ejemplares similares